Eagle Pharmaceuticals has for now averted the impending suspension and removal of its shares from the Nasdaq Capital Market list after earlier being pulled up by the stock exchange for failure to timely file important financial information.
The Nasdaq had earlier initiated a process to delist the company’s securities because of Eagle’s negligence in filing both its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?